Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repligen has acquired the business of Novozymes Biopharma Sweden for EUR 17m, following which Repligen will supply products to manufacture biologic drugs.
Subscribe to our email newsletter
The transaction involves future milestone payments of EUR 4m.
The acquisition is believed to expand Repligen’s product offering, customer base and manufacturing capacity.
The combined company will also drive the growth of the monoclonal antibody market.
Novozymes Biopharma manufactures and supplies growth factors used in mammalian cell culture and Protein A affinity ligands used in the production of monoclonal antibodies, under cGMP.